This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Otonomy マネジメント

マネジメント基準チェック /04

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	1.8yrs
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

CEO（最高経営責任者

Otonomy CEOがいない、あるいは彼らに関するデータがない。

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Maggio	President & Secretary	less than a year	データなし	データなし
Allen Ryan	Co-Founder and Member of the Advisory Panel	no data	データなし	データなし
Rick Friedman	Co-Founder and Member of the Advisory Panel	no data	データなし	データなし
Breianna Bowen	Vice President of Human Resources	1.6yrs	データなし	データなし
Barbara Finn	Senior Vice President of Regulatory Affairs & Quality Assurance	1.9yrs	データなし	データなし
Fabrice Piu	Senior Vice President of Preclinical Development	1.9yrs	データなし	データなし
David Skarinsky	Senior Vice President of Clinical	1.9yrs	データなし	データなし
James Branch	VP of Finance & Controller	1.6yrs	データなし	データなし
Jeffery Anderson	Vice President of Clinical Sciences	no data	データなし	データなし

1.8yrs

平均在職期間

経験豊富な経営陣: 7OT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

This company listing is no longer active

Otonomy マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Otonomy, Inc. Announces Executive Changes

Otonomy, Inc. Announces Executive Changes

Otonomy, Inc. Announces Departure of Robert Michael Savel II, as Chief Technical Officer Effective August 15, 2022

Recent updates

Otonomy, Inc. Announces Executive Changes

Otonomy, Inc.(OTCPK:OTIC) dropped from Russell 3000E Value Index

Otonomy, Inc. Announces Executive Changes

Otonomy, Inc Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Otonomy Receives Non-Compliance Letter from Nasdaq

Otonomy, Inc. Announces Departure of Robert Michael Savel II, as Chief Technical Officer Effective August 15, 2022

Otonomy Reports Results from Phase 2 Clinical Trial of Oto-313 in Patients with Tinnitus

Otonomy, Inc. to Report Q2, 2022 Results on Jul 25, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.23 loss in 1Q 2021)

Otonomy, Inc. to Report Q1, 2022 Results on May 09, 2022

Otonomy, Inc. Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Otonomy, Inc. Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus

Otonomy, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Otonomy Reports Corporate and Product Pipeline Update

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.22 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.37 loss in 2Q 2020)

Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for Oto-413 in Hearing Loss

ALK-Abelló A/S (CPSE:ALK B) acquired OTIPRIO from Otonomy, Inc. (NasdaqGS:OTIC).

Otonomy, Inc. and Applied Genetic Technologies Corporation Present Preclinical Proof-Of-Concept Results for Oto-825 Gene Therapy At ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.38 loss in 1Q 2020)

Otonomy, Inc. Announces to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

New 90-day low: €2.33

Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease

Full year 2020 earnings released: US$1.10 loss per share (vs US$1.45 loss in FY 2019)

Revenue misses expectations

Otonomy, Inc. to Report Q4, 2020 Results on Feb 11, 2021

New 90-day high: €5.29

Otonomy, Inc. Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss

New 90-day high: €4.37

Otonomy, Inc. Provides Update on Otividex® and Oto-313 Programs

Revenue misses expectations

Third quarter 2020 earnings released: US$0.22 loss per share

Otonomy, Inc. to Report Q3, 2020 Results on Nov 04, 2020

New 90-day high: €4.02

Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX in Ménière’s Disease

New 90-day high - €3.85

First half earnings released

Otonomy, Inc. to Report Q2, 2020 Results on Aug 04, 2020

Otonomy, Inc. has completed a Follow-on Equity Offering in the amount of $60.121 million.

Otonomy, Inc.(NasdaqGS:OTIC) dropped from Russell Microcap Value Index

CEO（最高経営責任者

リーダーシップ・チーム

平均在職期間

マネジメント基準チェック /04